Hepatocellular Carcinoma: A Comprehensive Review of Pathophysiology, Risk Factors, Diagnosis and Treatment Strategies

Authors

  • Vedika N. Dafe Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.
  • Pooja R. Hatwar Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India. https://orcid.org/0009-0002-6439-585X
  • Ravindra L. Bakal Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.
  • Harshdeep V. Bindod Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Abstract

Hepatocellular carcinoma (HCC) is a major cause of death in cirrhosis and the fourth most common cause of cancer-related mortality globally. Chronic liver diseases, such as cirrhosis and viral hepatitis, significantly increase the risk of HCC. Early detection and treatment are vital to improving patient outcomes. HCC development involves complex interactions between liver cells, genetic changes, and environmental factors. Diagnostic approaches include imaging tests, biomarkers, and liquid biopsy. Current treatments comprise surgery, liver transplantation, radiation therapy, and systemic therapies. Preventing HCC through lifestyle changes, such as reducing alcohol intake and maintaining a healthy weight, is crucial. Understanding HCC's molecular mechanisms is essential for developing effective treatments and improving patient outcomes.

Keywords: Hepatocellular carcinoma, Cancer diagnosis, Cirrhosis, chronic liver disease

Keywords:

Hepatocellular carcinoma, Cancer diagnosis, Cirrhosis, chronic liver disease

DOI

https://doi.org/10.22270/jddt.v15i5.7123

Author Biographies

Vedika N. Dafe, Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Pooja R. Hatwar , Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Ravindra L. Bakal , Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Harshdeep V. Bindod, Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangaon Rly, Dist -Amravati (444709) Maharashtra, India.

References

1. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61. https://doi.org/10.1016/bs.acr.2020.10.001 PMid:33579421 PMCid:PMC8796122

2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. https://doi.org/10.1038/s41575-019-0186-y PMid:31439937 PMCid:PMC6813818

3. Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27(1):85-102. https://doi.org/10.1016/j.cld.2022.08.004 PMid:36400469

4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2 PMid:29307467

5. Foglia B, Turato C, Cannito S. Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment. Int J Mol Sci. 2023;24(15):12224. https://doi.org/10.3390/ijms241512224 PMid:37569600 PMCid:PMC10419038

6. Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, Feng Y, Chen ZS, Wang N. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23(1):189. https://doi.org/10.1186/s12943-024-02101-z PMid:39242496 PMCid:PMC11378508

7. Ren Z, Ma X, Duan Z, Chen X. Diagnosis, Therapy, and Prognosis for Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2020;2020:8157406. https://doi.org/10.1155/2020/8157406 PMid:32089989 PMCid:PMC7023837

8. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2011;7(1):16-24.

9. Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024;31(8):1105-1112. https://doi.org/10.1038/s41417-024-00764-w PMid:38499648 PMCid:PMC11327108

10. Berk LB. Hepatocellular carcinoma: fighting the rising tide. Cancer Control. 2010;17(2):68-69. https://doi.org/10.1177/107327481001700201 PMid:20404789

11. Gabbia D, De Martin S. Insights into Hepatocellular Carcinoma: From Pathophysiology to Novel Therapies. Int J Mol Sci. 2024;25(8):4188. https://doi.org/10.3390/ijms25084188 PMid:38673774 PMCid:PMC11049888

12. Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol. 2023;29(2):343-356. https://doi.org/10.3748/wjg.v29.i2.343 PMid:36687125 PMCid:PMC9846942

13. Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559177/ .

14. Vyas M, Zhang X. Hepatocellular Carcinoma: Role of Pathology in the Era of Precision Medicine. Clin Liver Dis. 2020;24(4):591-610. https://doi.org/10.1016/j.cld.2020.07.010 PMid:33012447

15. Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6 (2021). https://doi.org/10.1038/s41572-020-00240-3 PMid:33479224

16. Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Future Oncol. 2021;17(10):1237-1251. https://doi.org/10.2217/fon-2020-0758 PMid:33307782

17. Kelly D, Sharif K, Brown RM, Morland B. Hepatocellular carcinoma in children. Clin Liver Dis. 2015;19(2):433-447. https://doi.org/10.1016/j.cld.2015.01.010 PMid:25921672

18. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348-1361. https://doi.org/10.1016/j.jhep.2022.01.014 PMid:35589255 PMCid:PMC9126418

19. Chonprasertsuk S, Vilaichone RK. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn J Clin Oncol. 2017;47(4):294-297. https://doi.org/10.1093/jjco/hyw197 PMid:28042136

20. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1(Suppl 1):4-13. https://doi.org/10.1002/hep.31288 PMid:32319693 PMCid:PMC7577946

21. Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol. 2013;19(47):8887-94. https://doi.org/10.3748/wjg.v19.i47.8887 PMid:24379612 PMCid:PMC3870540

22. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther. 2011;16(6):787-795. https://doi.org/10.3851/IMP1895 PMid:21900710

23. Polpichai N, Saowapa S, Danpanichkul P, Chan SY, Sierra L, Blagoie J, Rattananukrom C, Sripongpun P, Kaewdech A. Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma. J Clin Med. 2024;13(22):6770. https://doi.org/10.3390/jcm13226770 PMid:39597914 PMCid:PMC11594971

24. Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel). 2022 Aug 22;14(16):4051. https://doi.org/10.3390/cancers14164051 PMid:36011044 PMCid:PMC9406638

25. George ES, Sood S, Broughton A, Cogan G, Hickey M, Chan WS, Sudan S, Nicoll AJ. The Association between Diet and Hepatocellular Carcinoma: A Systematic Review. Nutrients. 2021;13(1):172. https://doi.org/10.3390/nu13010172 PMid:33430001 PMCid:PMC7826815

26. Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol. 2015 Jan 27;7(1):101-12. https://doi.org/10.4254/wjh.v7.i1.101 PMid:25625001 PMCid:PMC4295187

27. Wang P, Berzin TM, Glissen Brown JR, Bharadwaj S, Becq A, Xiao X, Liu P, Li L, Song Y, Zhang D, Li Y, Xu G, Tu M, Liu X. Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study. Gut. 2019;68(10):1813-1819. https://doi.org/10.1136/gutjnl-2018-317500 PMid:30814121 PMCid:PMC6839720

28. O'Leary C, Mahler M, Soulen MC. Curative-Intent Therapies in Localized Hepatocellular Carcinoma. Curr Treat Options Oncol. 2020;21(4):31. https://doi.org/10.1007/s11864-020-0725-3 PMid:32193784

29. Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(21):8165. https://doi.org/10.3390/ijms21218165 PMid:33142892 PMCid:PMC7662786

30. Akkari I, Jaziri H. Monitoring of hepatocellular carcinoma. World J Gastroenterol. 2024;30(8):991-993. https://doi.org/10.3748/wjg.v30.i8.991 PMid:38516232 PMCid:PMC10950649

31. Parikh ND, Pillai A. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol. 2021;19(10):2020-2024. https://doi.org/10.1016/j.cgh.2021.05.045 PMid:34116048

32. Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma - A Multidisciplinary Approach. Int J Mol Sci. 2019;20(6):1465. https://doi.org/10.3390/ijms20061465 PMid:30909504 PMCid:PMC6470895

33. Crook CJ, Li D. Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma. Curr Oncol Rep. 2023;25(10):1191-1201. https://doi.org/10.1007/s11912-023-01455-9 PMid:37688739 PMCid:PMC10556166

34. Koga H, Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. Clin Mol Hepatol. 2023;29(2):242-251. https://doi.org/10.3350/cmh.2023.0102 PMid:36941079 PMCid:PMC10121288

35. Li H, Zhang L. Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy. Oncotarget. 2017;8(1):1805-1813. https://doi.org/10.18632/oncotarget.12101 PMid:27655683 PMCid:PMC5352100

Published

2025-05-15
Statistics
Abstract Display: 829
PDF Downloads: 588
PDF Downloads: 79

How to Cite

1.
Dafe VN, Hatwar PR, Bakal RL, Bindod HV. Hepatocellular Carcinoma: A Comprehensive Review of Pathophysiology, Risk Factors, Diagnosis and Treatment Strategies. J. Drug Delivery Ther. [Internet]. 2025 May 15 [cited 2026 Jan. 22];15(5):159-65. Available from: https://jddtonline.info/index.php/jddt/article/view/7123

How to Cite

1.
Dafe VN, Hatwar PR, Bakal RL, Bindod HV. Hepatocellular Carcinoma: A Comprehensive Review of Pathophysiology, Risk Factors, Diagnosis and Treatment Strategies. J. Drug Delivery Ther. [Internet]. 2025 May 15 [cited 2026 Jan. 22];15(5):159-65. Available from: https://jddtonline.info/index.php/jddt/article/view/7123